Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Antidiabetic Rosiglitazone Remodels the Adipocyte Transcriptome by Redistributing Transcription to PPARg-Driven Enhancers [Affymetrix]


ABSTRACT: Rosiglitazone (rosi) is a powerful insulin sensitizer, but serious toxicities have curtailed its widespread clinical use. Rosi functions as a high-affinity ligand for PPARg, the adipocyte-predominant nuclear receptor (NR). The classic model, involving binding of ligand to the NR on DNA, explains positive regulation of gene expression, but ligand-dependent repression is not well understood. We have now addressed this issue by studying the direct effects of rosiglitazone on gene transcription, using global run-on sequencing (GRO-seq). Rosi-induced changes in gene body transcription were pronounced after 10 minutes and correlated with steady-state mRNA levels as well as with transcription at nearby enhancers (eRNAs). Upregulated eRNAs occurred almost exclusively at PPARg binding sites, to which rosi treatment recruited the coactivator MED1. By contrast, transcriptional repression by rosi involved a loss of MED1 from eRNA sites devoid of PPARg and enriched for other TFs including AP-1 factors and C/EBPs. Thus, rosi activates and represses transcription by fundamentally different mechanisms that could inform the future development of antidiabetic drugs. Mature 3T3-L1 were treated with rosi or DMSO. Steady-state mRNA levels were monitored at various time points after the treatment between 0 minutes and 48 hours using Affymetrix Mouse Gene 1.1 ST Array.

ORGANISM(S): Mus musculus

SUBMITTER: Hee-Woong Lim 

PROVIDER: E-GEOD-56688 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPARγ-driven enhancers.

Step Sonia E SE   Lim Hee-Woong HW   Marinis Jill M JM   Prokesch Andreas A   Steger David J DJ   You Seo-Hee SH   Won Kyoung-Jae KJ   Lazar Mitchell A MA  

Genes & development 20140501 9


Rosiglitazone (rosi) is a powerful insulin sensitizer, but serious toxicities have curtailed its widespread clinical use. Rosi functions as a high-affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ), the adipocyte-predominant nuclear receptor (NR). The classic model, involving binding of ligand to the NR on DNA, explains positive regulation of gene expression, but ligand-dependent repression is not well understood. We addressed this issue by studying the direct effects of ro  ...[more]

Similar Datasets

2014-05-02 | E-GEOD-56745 | biostudies-arrayexpress
2014-05-02 | GSE56688 | GEO
2014-05-02 | GSE56745 | GEO
2012-07-10 | GSE39233 | GEO
2012-07-09 | E-GEOD-39233 | biostudies-arrayexpress
2019-01-11 | GSE115421 | GEO
2013-08-01 | E-GEOD-49423 | biostudies-arrayexpress
2010-04-08 | E-GEOD-12929 | biostudies-arrayexpress
2011-02-11 | E-GEOD-21329 | biostudies-arrayexpress
2007-08-20 | GSE8658 | GEO